NO871071L - Vaksiner. - Google Patents

Vaksiner.

Info

Publication number
NO871071L
NO871071L NO871071A NO871071A NO871071L NO 871071 L NO871071 L NO 871071L NO 871071 A NO871071 A NO 871071A NO 871071 A NO871071 A NO 871071A NO 871071 L NO871071 L NO 871071L
Authority
NO
Norway
Prior art keywords
host
vaccine
interferon
antibodies
effective amount
Prior art date
Application number
NO871071A
Other languages
English (en)
Norwegian (no)
Other versions
NO871071D0 (no
Inventor
John Hugh Lyon Playfair
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868606559A external-priority patent/GB8606559D0/en
Priority claimed from GB868606560A external-priority patent/GB8606560D0/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO871071D0 publication Critical patent/NO871071D0/no
Publication of NO871071L publication Critical patent/NO871071L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO871071A 1986-03-17 1987-03-16 Vaksiner. NO871071L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868606559A GB8606559D0 (en) 1986-03-17 1986-03-17 Vaccines
GB868606560A GB8606560D0 (en) 1986-03-17 1986-03-17 Vaccines

Publications (2)

Publication Number Publication Date
NO871071D0 NO871071D0 (no) 1987-03-16
NO871071L true NO871071L (no) 1987-09-18

Family

ID=26290503

Family Applications (1)

Application Number Title Priority Date Filing Date
NO871071A NO871071L (no) 1986-03-17 1987-03-16 Vaksiner.

Country Status (13)

Country Link
EP (1) EP0241725B1 (cs)
JP (1) JPH0832633B2 (cs)
AU (1) AU607130B2 (cs)
CA (1) CA1323302C (cs)
DE (1) DE3782960T2 (cs)
DK (1) DK175283B1 (cs)
ES (1) ES2052503T3 (cs)
FI (1) FI93423C (cs)
GR (1) GR3007080T3 (cs)
IE (1) IE59927B1 (cs)
IL (1) IL81920A (cs)
NO (1) NO871071L (cs)
NZ (1) NZ219631A (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
ATE112686T1 (de) * 1990-08-31 1994-10-15 Schering Corp Verwendungsmethoden von humanem gammainterferon 4-134.
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
GB9725480D0 (en) * 1997-12-01 1998-01-28 Univ London Cytokines and their use in the treatment of established chronic infections and cancers
WO2004028561A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 免疫応答誘導方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US4938956A (en) * 1987-04-01 1990-07-03 International Minerals & Chemical Corp. Synergistic immunostimulating composition and method

Also Published As

Publication number Publication date
AU607130B2 (en) 1991-02-28
DK175283B1 (da) 2004-08-09
AU7008687A (en) 1987-09-24
NZ219631A (en) 1990-03-27
EP0241725A3 (en) 1989-05-10
EP0241725A2 (en) 1987-10-21
DK133287A (da) 1987-09-18
JPS62277328A (ja) 1987-12-02
EP0241725B1 (en) 1992-12-09
FI93423C (fi) 1995-04-10
CA1323302C (en) 1993-10-19
FI871131A0 (fi) 1987-03-16
DE3782960T2 (de) 1993-04-29
IL81920A (en) 1991-12-12
GR3007080T3 (cs) 1993-07-30
IL81920A0 (en) 1987-10-20
FI871131L (fi) 1987-09-18
JPH0832633B2 (ja) 1996-03-29
FI93423B (fi) 1994-12-30
IE870684L (en) 1987-09-17
ES2052503T3 (es) 1994-07-16
NO871071D0 (no) 1987-03-16
DK133287D0 (da) 1987-03-16
IE59927B1 (en) 1994-05-04
DE3782960D1 (de) 1993-01-21

Similar Documents

Publication Publication Date Title
Heppner et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes
JP5108521B2 (ja) マラリア初回免疫／追加免疫ワクチン
Ben-Yedidia et al. Design of peptide and polypeptide vaccines
US20060292170A1 (en) Vaccine Composition Against Malaria
Rivier et al. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection
Hoffman et al. Progress toward malaria preerythrocytic vaccines
Gordon et al. Safety and immunogenicity of a Plasmodium vivax sporozoite vaccine
US4957738A (en) Protein copolymer malaria vaccine
MX2014000727A (es) Plasmodium atenuado con el gen hmgb2 desactivado como vacuna.
NO871071L (no) Vaksiner.
Kierszenbaum Chagas’ disease
JPS63239296A (ja) マラリアワクチン
Clough et al. Biologically active antibodies elicited by a synthetic circumsporozoite peptide of Plasmodium knowlesi administered in saline with a muramyl dipeptide derivative
US20060073171A1 (en) Vaccine composition against malaria
CN100333791C (zh) 抗疟疾的疫苗接种方法
Nussenzweig et al. Experimental basis for the development of a synthetic vaccine against Plasmodium falciparum malaria sporozoites
WO2000073465A1 (fr) Peptides capables d'induire des cellules tueuses specifiques du vih et agents prophylactiques/medicaments contre le vih contenant ces peptides
Riddell et al. Tropical disease vaccines
Ballou et al. The development of molecular vaccines against malaria sporozoites
Ballou et al. Stanley J. Cryztt, and Jerald C. Sadoff
Desowitz Great Expectations: Malaria Vaccines and Antimalaria Drugs for the Next Century